Literature DB >> 20359260

Multiple sclerosis in the elderly patient.

Amer Awad1, Olaf Stüve.   

Abstract

Multiple sclerosis (MS) is an acquired inflammatory demyelinating disease of the CNS that is typically diagnosed in the second or third decade of life. It is generally believed that over the last few decades the life expectancy of patients with adult onset MS (AOMS) has approached that of the general population as a result of better medical and nursing care. Thus, an increasing number of MS patients are entering or have reached senescence. A second group of elderly patients with MS that may be very different in terms of disease pathogenesis are patients with late onset MS (LOMS). The diagnosis in LOMS patients can be challenging because of a large number of age-associated MS differential diagnoses, atypical presentations, a low index of suspicion and the lack of diagnostic criteria specific to this age group. Also, specific problems these patients encounter have only recently become a focus of attention. Changes in renal and hepatic function with age, in addition to the coexistence of medical co-morbidities, require special attention in the management of elderly patients with MS. In this review we outline the characteristics of senescent AOMS and LOMS patients. In addition, we discuss therapeutic strategies in elderly patients with MS based on our knowledge of immunosenescence and age-associated characteristics of this disorder. Given the overall aging of the population, focusing on these two patient groups appears highly relevant.

Entities:  

Mesh:

Year:  2010        PMID: 20359260     DOI: 10.2165/11532120-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  139 in total

1.  Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.

Authors:  R Yuan; J Venitz
Journal:  Int J Clin Pharmacol Ther       Date:  2000-05       Impact factor: 1.366

2.  A full genome search in multiple sclerosis.

Authors:  G C Ebers; K Kukay; D E Bulman; A D Sadovnick; G Rice; C Anderson; H Armstrong; K Cousin; R B Bell; W Hader; D W Paty; S Hashimoto; J Oger; P Duquette; S Warren; T Gray; P O'Connor; A Nath; A Auty; L Metz; G Francis; J E Paulseth; T J Murray; W Pryse-Phillips; R Nelson; M Freedman; D Brunet; J P Bouchard; D Hinds; N Risch
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

3.  Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

Authors:  Hillel Panitch; Aaron Miller; Donald Paty; Brian Weinshenker
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

4.  Revised estimate of the prevalence of multiple sclerosis in the United States.

Authors:  D W Anderson; J H Ellenberg; C M Leventhal; S C Reingold; M Rodriguez; D H Silberberg
Journal:  Ann Neurol       Date:  1992-03       Impact factor: 10.422

5.  APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score.

Authors:  Georgios Koutsis; Marios Panas; Georgia Karadima; Dimitris Mandellos; Constantinos Sfagos; Constantin Potagas; Demetris Vassilopoulos
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

Review 6.  Primary progressive multiple sclerosis.

Authors:  A J Thompson; C H Polman; D H Miller; W I McDonald; B Brochet; X Filippi M Montalban; J De Sá
Journal:  Brain       Date:  1997-06       Impact factor: 13.501

7.  European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Authors:  G Comi; M Filippi; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

8.  The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study.

Authors:  G G Steinmann; B Klaus; H K Müller-Hermelink
Journal:  Scand J Immunol       Date:  1985-11       Impact factor: 3.487

9.  Multiple sclerosis after age 50.

Authors:  J Noseworthy; D Paty; T Wonnacott; T Feasby; G Ebers
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

10.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  12 in total

1.  Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis.

Authors:  Natalie A Schwehr; Karen M Kuntz; Eva A Enns; Nathan D Shippee; Elaine Kingwell; Helen Tremlett; Adam F Carpenter; Mary Butler
Journal:  Drugs Aging       Date:  2020-03       Impact factor: 3.923

2.  Self-efficacy and Physical and Cognitive Function in Older Adults with Multiple Sclerosis.

Authors:  Rachel E Bollaert; Robert W Motl
Journal:  Int J MS Care       Date:  2019 Mar-Apr

3.  Cognition in older patients with multiple sclerosis compared to patients with amnestic mild cognitive impairment and healthy older adults.

Authors:  Alexandra K Roth; Douglas R Denney; Jeffrey M Burns; Sharon G Lynch
Journal:  Neuropsychology       Date:  2018-06-25       Impact factor: 3.295

4.  Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment.

Authors:  Afsaneh Shirani; Yinshan Zhao; John Petkau; Paul Gustafson; Mohammad Ehsanul Karim; Charity Evans; Elaine Kingwell; Mia L van der Kop; Joel Oger; Helen Tremlett
Journal:  Biomed Res Int       Date:  2015-04-01       Impact factor: 3.411

5.  Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.

Authors:  Kishore Malyavantham; Bianca Weinstock-Guttman; Lakshmanan Suresh; Robert Zivadinov; Thomas Shanahan; Darlene Badgett; Murali Ramanathan
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

6.  Downregulation of inhibitory SRC homology 2 domain-containing phosphatase-1 (SHP-1) leads to recovery of T cell responses in elderly.

Authors:  Aurélie Le Page; Carl Fortin; Hugo Garneau; Nancy Allard; Krassimira Tsvetkova; Crystal Tze Ying Tan; Anis Larbi; Gilles Dupuis; Tamas Fülöp
Journal:  Cell Commun Signal       Date:  2014-01-09       Impact factor: 5.712

7.  Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?

Authors:  Raed Alroughani; Saeed Akhtar; Samar Ahmed; Raed Behbehani; Jasem Al-Hashel
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

8.  Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.

Authors:  Huah Shin Ng; Jonas Graf; Feng Zhu; Elaine Kingwell; Orhan Aktas; Philipp Albrecht; Hans-Peter Hartung; Sven G Meuth; Charity Evans; John D Fisk; Ruth Ann Marrie; Yinshan Zhao; Helen Tremlett
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

9.  Levels and Rates of Physical Activity in Older Adults with Multiple Sclerosis.

Authors:  Rachel E Klaren; Emerson Sebastiao; Chung-Yi Chiu; Dominique Kinnett-Hopkins; Edward McAuley; Robert W Motl
Journal:  Aging Dis       Date:  2016-05-27       Impact factor: 6.745

10.  Feasibility study design and methods for a home-based, square-stepping exercise program among older adults with multiple sclerosis: The SSE-MS project.

Authors:  Emerson Sebastião; Edward McAuley; Ryosuke Shigematsu; Robert W Motl
Journal:  Contemp Clin Trials Commun       Date:  2017-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.